VZV NC (0371): sc-58082



The Power to Question

BACKGROUND

Varicella Zoster Virus, known as VZV, is an ubiquitous human alphaherpesvirus that causes two distinct diseases: childhood chickenpox (Varicella) and shingles (Zoster). VZV becomes dormant in sensory ganglia and may reactivate decades later to produce Zoster (shingles) or herpes Zoster. VZV is enveloped in the *trans*-Golgi network (TGN). The VZV virion contains an icosahedral nucleocapsid surrounding a core that contains the linear, double-stranded DNA genome as well as a protein tegument that separates the capsid from the lipid envelope. This envelope incorporates all of the major viral glycoproteins. The VZV nucleocapsid protein, which is encoded by VZV gene 40, induces a humoral immune response in infected individuals.

REFERENCES

- Vlazny, D.A. and Hyman, R.W. 1985. Errant processing and structural alterations of genomes present in a Varicella Zoster Virus vaccine. J. Virol. 56: 92-101.
- Vafai, A., Wroblewska, Z. and Graf, L. 1990. Antigenic cross-reaction between a Varicella Zoster Virus nucleocapsid protein encoded by gene 40 and a herpes simplex virus nucleocapsid protein. Virus Res. 15: 163-174.
- Harson, R. and Grose, C. 1995. Egress of Varicella Zoster Virus from the melanoma cell: a tropism for the melanocyte. J. Virol. 69: 4994-5010.
- 4. Arvin, A.M. 1996. Varicella Zoster Virus. Clin. Microbiol. Rev. 9: 361-381.
- Cohen, J.I. 1996. Varicella Zoster Virus. The virus. Infect. Dis. Clin. North Am. 10: 457-468.
- Harper, D.R., Gilbert, R.L. and Jeffries, D.J. 1998. Molecular biology of Varicella Zoster Virus. A review prepared for the UK Advisory Group on Chickenpox. J. Infect. 36: 1-10.
- Lloyd-Evans, P. and Gilmour, J.E. 2000. Expression of neutralizing recombinant human antibodies against Varicella Zoster Virus for use as a potential prophylactic. Hybridoma 19: 143-149.
- 8. Cohrs, R.J., Wischer, J., Essman, C. and Gilden, D.H. 2002. Characterization of Varicella Zoster Virus gene 21 and 29 proteins in infected cells. J. Virol. 76: 7228-7238.
- 9. Visalli, R.J., Fairhurst, J., Srinivas, S., Hu, W., Feld, B., DiGrandi, M., Curran, K., Ross, A., Bloom, J.D., van Zeijl, M., Jones, T.R., O'Connell, J. and Cohen, J.I. 2003. Identification of small molecule compounds that selectively inhibit Varicella Zoster Virus replication. J. Virol. 77: 2349-2358.

SOURCE

VZV NC (0371) is a mouse monoclonal antibody raised against VZV nucleocapsid.

PRODUCT

Each vial contains 100 $\mu g \; lg G_1$ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

VZV NC (0371) is recommended for detection of VZV nucleocapsid by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com